Table of Contents
- What Kratom Alkaloids Are (Beginner Basics)
- Mitragynine Explained: The Primary Alkaloid
- 7-Hydroxymitragynine Explained: The Minor Alkaloid With a Big Reputation
- Other Alkaloids Found in Kratom Leaf
- Kratom Alkaloids and Brain Chemistry: What the Research Suggests
- What a Kratom Alkaloid Profile Actually Tells You
- Evidence Quality and Safety: Reading Kratom Claims Carefully
- Conclusion
- Frequently Asked Questions
Last Updated: October 18, 2026
What Kratom Alkaloids Are (Beginner Basics)
Kratom alkaloids are the natural nitrogen-containing compounds found in the leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia.
Think of alkaloids as the plant’s chemical signature. Every leaf carries a mix of them, and that mix shifts with age, origin, and how the plant material is dried and handled, so two batches of the same strain can differ noticeably.
Why Alkaloids Matter More Than Leaf Color
Leaf color tells you almost nothing about chemistry. A red, green, or white label describes how the leaf was dried and fermented, not what compounds remain inside.
What matters is the alkaloid profile: which compounds are present and in what proportion, shaped by genetics, harvest timing, and processing. A dark red powder and a bright green powder can share a nearly identical composition, or differ widely.
Mitragynine Explained: The Primary Alkaloid
Mitragynine is the most abundant alkaloid in kratom leaf, typically making up the largest share of total alkaloid content. It is the compound most laboratory studies focus on and the one that anchors nearly every alkaloid profile discussed.
Here is the honest part most beginner guides skip: almost all of what we know about mitragynine comes from laboratory studies, not clinical research in humans.
What the research suggests, in plain terms:
- Mitragynine binds to opioid receptors, but its chemical structure differs from classic opioids
- It is also metabolized by the body into related compounds, including 7-hydroxymitragynine
- Potency and effects depend heavily on dose and on everything else in the leaf
Treat mitragynine as the headline compound, not a guarantee of anything.
7-Hydroxymitragynine Explained: The Minor Alkaloid With a Big Reputation
7-hydroxymitragynine is a minor alkaloid present at far lower levels than mitragynine.
That “more potent” label gets repeated everywhere, but quantity gets left out. A compound that is more potent per molecule yet present in tiny amounts does not automatically dominate the plant’s character.
There is also a conversion story. Some research suggests mitragynine can convert into 7-hydroxymitragynine during metabolism, and possibly during certain processing steps, so reading one without the other gives an incomplete picture.
Other Alkaloids Found in Kratom Leaf
Before comparing the minor players, lock down the vocabulary, because most beginner confusion starts with words, not chemistry.
- Alkaloid: a naturally occurring, nitrogen-containing compound produced by a plant. The nitrogen is what makes it chemically interesting, it lets the molecule interact with receptors in a living system.
- Bioactive compound: any substance that produces an effect on living tissue. Not all alkaloids are bioactive in a meaningful way, and “bioactive” says nothing about whether an effect is strong, weak, helpful, or risky.
- Receptor: a protein on or inside a cell that a compound can bind to, like a lock waiting for a key. Binding is not the same as activating, a compound can block a receptor, partially trigger it, or trigger it strongly.
With those terms in hand, the minor alkaloids become easier to read. Kratom leaf carries dozens of them, each at low levels.
| Alkaloid | Relative abundance | What the evidence supports |
|---|---|---|
| Mitragynine | Major, the largest single share of total alkaloids | Laboratory receptor studies; the most-studied compound in the plant |
| 7-hydroxymitragynine | Minor, present at far lower levels than mitragynine | Laboratory work suggesting stronger receptor binding per molecule; quantity is small |
| Ajmalicine | Minor | Studied in other plants; role in kratom is an open question |
| Raubasine | Minor | Same as above, low levels, limited kratom-specific research |
| Paynantheine | Minor | Identified in kratom; comparatively little published work |
| Speciogynine | Minor | Identified in kratom; comparatively little published work |
| Speciociliatine | Minor | Identified in kratom; comparatively little published work |
| Corynantheidine | Minor | Identified in kratom; comparatively little published work |
Two things stand out from that table. First, the gap between mitragynine and everything else is large, the minors are genuinely minor in quantity.
Ajmalicine and Raubasine
Ajmalicine and raubasine are two of the better-known minor alkaloids in kratom. Both appear in other plants and have been studied outside kratom research, which is precisely why beginners should be careful.
In kratom, they appear at low levels. Treat them as supporting plant compounds, not the main event; their exact contribution to the overall alkaloid profile remains an open research question.
Minor Alkaloids and the Entourage Question
The “entourage effect” is the idea that minor compounds work together with primary ones to shape a plant’s overall character.
Here is the catch: for kratom specifically, the entourage question is largely unresolved. Laboratory studies mostly isolate single compounds and test them one at a time.
Hold it this way: the entourage effect is a reasonable hypothesis, not an established mechanism.
Kratom Alkaloids and Brain Chemistry: What the Research Suggests
This is where claims outrun evidence fastest. The core finding is real: mitragynine and 7-hydroxymitragynine both interact with opioid receptors in laboratory settings, and that interaction underlies most effects discussed in the literature. But “interacts with a receptor in a lab dish” and “produces a predictable outcome in a person” are very different statements, and the distance between them is the whole story.
A Plain-Language Mechanism
Here is the chain, step by step, in beginner terms:
- Binding. A compound reaches a receptor, a protein that acts like a lock. Mitragynine and 7-hydroxymitragynine can fit opioid receptors, which is why they are described as interacting with them.
- Partial activation. Binding is not all-or-nothing. A compound can trigger a receptor weakly, strongly, or partially, and different compounds produce different patterns at the same receptor.
- Metabolism. The body chemically alters compounds after they enter it. Mitragynine is metabolized into related compounds, including 7-hydroxymitragynine, so what enters the body is not exactly what acts on it.
- Dose dependence. The literature discusses lower and higher amounts differently, and effects described at one level do not automatically scale to another.
That four-step chain is the honest summary. Everything beyond it is where the evidence gets thin.
Sorting the Evidence by Tier
The single most useful skill a beginner can build is telling evidence types apart. Not all research carries the same weight.
| Evidence tier | What it looks like | What it can tell you | What it cannot |
|---|---|---|---|
| Laboratory (in vitro) | Isolated receptors or cells exposed to a compound | Whether binding or activity is plausible at the molecular level | Nothing about whole-body outcomes |
| Animal studies | Controlled experiments in non-human subjects | Whether a mechanism appears to function in a living system | Nothing certain about human responses |
| Human observational data | Reports and surveys, not controlled trials | Patterns worth investigating | Cause and effect |
| Human clinical trials | Controlled, randomized human studies | The strongest available evidence | Whether any exist in sufficient number |
For kratom alkaloids, most published work sits in the top two rows; clean human clinical trials with firm conclusions are scarce. That gap is why careful writers say “the research suggests” rather than “the research proves.”
What the Research Does and Does Not Support
Stated carefully, the literature supports the following:
- Receptor activity: the primary alkaloids bind to opioid receptors in laboratory settings, which is why effects are often described in terms of calming or soothing qualities
- Metabolism: the body processes mitragynine into related compounds, so the picture is dynamic rather than static
- Dose dependence: effects described in the literature shift with dose, and lower and higher amounts are discussed differently
What the literature does not support is any claim of a clean, predictable human outcome. Most evidence comes from laboratory and animal work, a gap that is not a footnote but the main finding for a beginner reading the field honestly.
Health Canada guidance on natural health products
If a claim about kratom alkaloids and brain chemistry cannot tell you which evidence tier it rests on, treat it as marketing rather than science. The mechanism is plausible; the human evidence is thin; the honest position is uncertainty.
What a Kratom Alkaloid Profile Actually Tells You
A kratom alkaloid profile is a breakdown of which alkaloids are present in a batch of plant material and in what relative amounts, a chemical snapshot, not a promise.
A useful profile tells you:
- Which primary alkaloids are present
- The rough ratio between mitragynine and 7-hydroxymitragynine
- Whether minor alkaloids like ajmalicine and raubasine show up
What it cannot tell you is how any person will respond. A profile describes plant material. It does not describe an outcome.
Why Alkaloid Content Varies From Batch to Batch
Alkaloid content is not fixed. It moves with the plant, not just the label.
The main drivers:
- Leaf age at harvest: younger and older leaves carry different chemical composition
- Origin and growing conditions: soil, climate, and plant genetics all shift the profile
- Drying and processing: how leaf is handled after harvest changes what remains
- Storage: plant material degrades over time, and poor storage speeds that up
This is why batch-to-batch variation is normal, and why a single lab report describes one batch, not a whole product line forever.
Evidence Quality and Safety: Reading Kratom Claims Carefully
Most kratom claims online are stronger than the evidence behind them, the single most useful thing a beginner can learn.
A quick way to sort claims:
| Claim type | What it usually rests on | How to read it |
|---|---|---|
| “Binds to opioid receptors” | Laboratory receptor studies | Plausible, but lab-only |
| “More potent than mitragynine” | Isolated compound comparisons | True per molecule, ignores quantity |
| “Entourage effect explains it all” | Theory, not kratom-specific proof | Interesting, unproven |
| “Works for everyone the same way” | Nothing reliable | Ignore it |
On safety, the honest position is uncertainty. If you take medication or have a health condition, talk to a healthcare professional before handling any botanical product.
At INDOKRATOM.CA, all botanical products are sold strictly for in vivo research only, not for human or animal consumption, and every batch is lab tested for safety and quality.
The most common beginner mistake is treating a potency claim as a dosage guide. “More potent per molecule” says nothing about how much of a compound is actually in the leaf. Confusing the two leads people to expect outcomes the chemistry never promised.
Conclusion
The gap between what kratom alkaloids do in a lab dish and what they do in a living body is the whole story. Mitragynine leads the profile, 7-hydroxymitragynine draws the attention, and the minor alkaloids remain an open question.
If you want plant material you can actually trace, INDOKRATOM.CA focuses on lab-tested botanical products, a straightforward ordering process, and clear product information. Browse the shop to see current options and batch details.
Frequently Asked Questions
What are the main alkaloids found in kratom?
Kratom leaf contains dozens of alkaloids, but two dominate the conversation: mitragynine and 7-hydroxymitragynine. Mitragynine is the most abundant, making up the largest share of the alkaloid content in most leaf material. 7-hydroxymitragynine appears in much smaller amounts but attracts attention because of how it interacts with opioid receptors in laboratory studies. Other named alkaloids include ajmalicine, raubasine, and a long list of minor compounds that researchers are still mapping. The exact mix, called the alkaloid profile, shifts with strain, growing conditions, harvest timing, and processing.
Is 7-hydroxymitragynine stronger than mitragynine?
In laboratory receptor studies, 7-hydroxymitragynine shows higher potency at opioid receptors than mitragynine, which is why it gets called the stronger of the two. That label needs context. It is present in far smaller quantities in raw leaf, so the total picture depends on the full alkaloid profile, not one compound. Concentrated extracts and solvent extraction can shift that ratio dramatically. Potency in a lab dish also does not translate directly to real-world effects, and evidence quality on this point is limited. Treat any simple stronger-or-weaker comparison as a starting point, not a conclusion.
How many alkaloids are found in kratom?
Published research has identified several dozen alkaloids in Mitragyna speciosa leaf, with counts commonly cited in the range of 40 or more bioactive compounds. Only a handful have been studied in any depth. Mitragynine and 7-hydroxymitragynine get most of the attention, while ajmalicine, raubasine, and various minor alkaloids remain poorly understood. The number matters less than the ratio: two batches can contain a similar total alkaloid content but very different profiles. That is one reason lab testing and batch consistency are worth asking about when comparing plant material.
Does kratom change your brain chemistry?
Kratom alkaloids interact with opioid receptors and other receptor systems in laboratory and animal studies, which is why researchers describe pharmacological activity rather than a permanent change. Whether that activity produces lasting changes in human brain chemistry is not established, and clinical research is thin. Evidence quality is a real limit here: most findings come from lab studies, not controlled human trials. Anyone weighing potential risks, interactions with medications, or dependence concerns should treat the uncertainty as meaningful and speak with a healthcare professional rather than relying on marketing claims.